# Geneoscopy

> GI diagnostics company — noninvasive colorectal cancer screening (ColoSense) and related tests.

## Why it is interesting

St. Louis GI diagnostics company that closed a $105M Series C (Jan 2025) led by Bio-Rad to commercialize ColoSense — RNA stool biomarker CRC screening with Labcorp distribution partnership.

## Profile

- **Latest funding:** Series C — $105M (January 2025)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $105M
- **Stage:** growth
- **Status:** private
- **Industries:** biotech-life-sciences, healthtech
- **Coverage:** full
- **Last updated:** 2026-07-26
- **Latest funding investors:** Bio-Rad Laboratories, Petrichor, Labcorp, Morningside Ventures, Lightchain Capital

## Key facts

- Series C (Jan 2025): $105M led by Bio-Rad Laboratories (company / GenomeWeb)
- Participants included Labcorp, Petrichor, Morningside Ventures, and others
- Lead product: ColoSense noninvasive CRC screening
- St. Louis, MO HQ

## Funding history

- Series C · $105M · January 2025
  Source: https://www.geneoscopy.com/geneoscopy-closes-105m-in-series-c-funding-round-to-power-next-generation-of-gastrointestinal-diagnostic-tests/

## Related articles

- https://venturecapitaltracker.com/st-louis-startups-and-vc-firms-2026

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** July 26, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/geneoscopy